[DiaPlexQ™ Novel Coronavirus(2019-nCoV) Detection Kit] 

Two COVID-19 diagnostic reagents developed by SolGent obtained CE (European Certification) on 28th. SolGent has been able to supply COVID-19 diagnostic reagents in Korea with the emergency approval of the Korea Centers for Disease Control and Prevention on 27th, and has pioneered a way to provide COVID-19 diagnostic reagents around the world with the acquisition of CE. CE is the certification required in most countries including Europe for the export of diagnostic reagents, and there are two CE acquired products in SolGent. 

[DiaPlexQ™ Novel Coronavirus(2019-nCoV) Detection Kit] 

SolGent's DiaPlexQ is a medical device for In-Vitro qualitative detection of the new COVID-19 gene (ORF1a gene and gene) from the samples of suspected patients. The device can diagnose quickly within two hours after extracting RiboNucleic Acid (RNA).

“It is very pleased to contribute to the stable supply of diagnostic reagents by obtaining CE following the emergency use. We are currently discussing large-scale orders with China and Vietnam where we supplied our test products before the CE approval. More than 20 countries have signed the supply agreement and the shipment will be delivered from March 2nd in order.” said by You-Jae Hyung, co-president of SolGent.